Evidence map›Paper›PMID 42288704›Full record

ArticleInternational journal of clinical oncology2026

Unveiling VARS1: a key driver of colorectal cancer progression and immune modulation.

Jiale Mei, Yuman Wu, Sicheng Zhao, Ning Qu, Haojun Xie, Dewei Guo, Tao Luo, Jiali Tang, Wenqi Luo

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiale Mei *Colorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Yuman Wu *Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Sicheng Zhao *Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Ning QuGuangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Haojun XieGuangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Dewei GuoGuangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Tao LuoColorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Jiali TangDepartment of Ultrasound, Guangxi Medical University Cancer Hospital, No.71 Hedi Road, Nanning, 530021, People's Republic of China. tangjiali@sr.gxmu.edu.cn.
Wenqi LuoDepartment of Pathology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China. h2017024@sr.gxmu.edu.cn.

Funding

Joint Project on the Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation 2024GXNSFBA010303
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Valyl-tRNA synthetase 1 (VARS1), an aminoacyl-tRNA synthetase, has been implicated in various cancers, but its role in CRC remains unclear. This study investigated the expression pattern, clinical significance, biological functions, and potential molecular associations of VARS1 in CRC.

methodsVARS1 expression was analyzed in CRC tissues using TCGA/GEO databases, immunohistochemistry, and Western blotting. Prognostic models were built via Cox regression and nomograms. In vitro, VARS1 was knocked down in CRC cell lines to assess proliferation (CCK-8, colony formation), migration/invasion (wound healing, Transwell), and EMT markers. Immune infiltration was evaluated with TIMER/CIBERSORT, single-cell analysis via Seurat/CellChat, drug sensitivity via GDSC2, and pathways via GO/KEGG/GSEA.

resultsVARS1 was overexpressed in CRC, correlating with poor survival as an independent risk factor. Knockdown suppressed cell proliferation, migration, invasion, accompanied by changes in EMT-related markers. High VARS1 expression was associated with reduced CD8

conclusionOur findings suggest that VARS1 is associated with malignant phenotypes, immune-related features, and chemotherapy response in CRC, and may serve as a potential prognostic biomarker.

Indexed as

Colorectal NeoplasmsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisTumor MicroenvironmentBiomarkers, TumorCRCEMTImmune infiltrationVARS1

Identifiers

PMID42288704

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.